Theravance Biopharma Inc (TBPH): יחס חוב להיוון בספרים

The price indicator on the Theravance Biopharma (TBPH) chart helps assess the effectiveness of alliances with global giants to promote respiratory therapies, with the metric standing at 0.24. The firm's environmental footprint is minimal, as production is outsourced to third-party contractors. However, the business faces severe pressure in the asthma treatment segment and risks the loss of patent protection.

This ratio determines the proportion of borrowed funds relative to equity, allowing for an assessment of the company's financial stability and credit risk level. Amid debt restructuring and the transition of Theravance Biopharma (TBPH) toward drug monetization, the history of the net debt-to-book value ratio becomes a key tool for monitoring the effectiveness of deleveraging without resorting to external mergers.